Glenmede Trust CO Na Cellectis S.A. Call Options Transaction History
Glenmede Trust CO Na
- $18.2 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
27Shares Held
13.2MCall Options Held
0Put Options Held
0-
Long Focus Capital Management, LLC San Juan, PR4.72MShares$15.8 Million0.33% of portfolio
-
B Group, Inc. Dallas, TX3.26MShares$10.9 Million3.82% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.18MShares$10.6 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$4.8 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$757,7620.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $152M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...